ClinicalTrials.gg
TerminatedNCT06587451Updated Feb 24, 2026

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

A Phase 3 interventional study of JPB898 (Induction and Maintenance) and Opdivo-EU (Induction) in Melanoma, sponsored by Sandoz. Terminated at 22 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

How we know · 8 judgments

Why this study was terminated
In light of the evolving regulatory landscape and growing indications that major Health Authorities will move towards a streamlined clinical development, Sandoz took a strategic decision and is winding down its CJPB898A12301 clinical study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Melanoma by Novartis — 1 open to participants now, 6 under way, none of them phase 3. Melanoma · Novartis.

Enrollment
31st of 35
52 · median 134
Started
2024
the only one that year
Phase 3
5 of 51
none open now
Registered
51st of 51
by date

Among the 51 studies in Melanoma by Novartis, this one is the 31st largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 3, and was the 51st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 51 studies in Melanoma by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Melanoma by Novartis, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate similar PK and efficacy and to show comparable safety and immunogenicity between JPB898, Opdivo-EU, and Opdivo-US, all administered in combination with Yervoy-EU (induction phase only), in participants with advanced (unresectable Stage III or metastatic Stage IV) melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants must be 18 years or older.
  • confirmed melanoma.
  • Unresectable or melanoma measurable by Computerized tomography (CT) or Magnetic resonance imaging (MRI).
  • (ECOG) performance status of 0 or 1.
  • Known Programmed cell death ligand 1 () and BRAF mutational status or consent to testing.
  • Sexually active participants must agree to use effective .

Exclusion criteria

Exclusion Criteria

  • Active brain or unless stable for 8 weeks.
  • Ocular melanoma.
  • Prior active within the last year untreated or still requiring treatment.
  • Severe and uncontrolled conditions, active /C, (HIV), or diseases requiring systemic treatment.
  • Previous treatment with specific , systemic anticancer therapy, or radiotherapy for melanoma.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    JPB898

    Participants will receive JPB898 combined with Yervoy-EU during the induction phase. Participants will receive JPB898 during maintenance phase.

    Drug: JPB898 (Induction and Maintenance) · Drug: Yervoy-EU (Induction)

  • Active comparator
    Opdivo-EU

    Participants will receive Opdivo-EU combined with Yervoy-EU during the induction phase. Participants will receive Opdivo-EU during the maintenance phase.

    Drug: Opdivo-EU (Induction) · Drug: Yervoy-EU (Induction) · Drug: Opdivo-EU (Maintenance)

  • Active comparator
    Opdivo-US

    Participants will receive Opdivo-US combined with Yervoy-EU during the induction phase. Participants will receive Opdivo-EU during the maintenance phase.

    Drug: Opdivo-US (Induction) · Drug: Yervoy-EU (Induction) · Drug: Opdivo-EU (Maintenance)

Interventions

06

What researchers measure

Primary outcomes

  1. Demonstrate PK similarity between JPB898, Opdivo-US, and Opdivo-EU

    Area under the serum concentration-time curve measured from the time of dosing of the first dose to the second dose (AUCtrunc) after the first dose

    Time frame: Days 1 to 22

  2. Demonstrate PK similarity between JPB898, Opdivo-US, and Opdivo-EU between JPB898 and Opdivo-US/-EU

    Area under the serum concentration-time curve measured from the time of dosing to the last measurable serum concentration in the dosing interval, tau (AUCtau) after the fourth dose

    Time frame: Days 64 to 85

  3. Demonstrate efficacy similarity for Best overall response (BOR) between JPB898 and Opdivo-US/-EU defined as the best overall response based on blinded central tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

    The assessment of response for the primary efficacy is based on tumor response data as per blinded independent central review and according to RECIST 1.1

    Time frame: BOR (Complete response (CR) or partial response (PR)) from baseline up to 28 weeks

07

Study locations

22 sites
  • Sandoz Investigational Site 1
    Santiago, Chile
  • Sandoz Investigational Site
    Santiago, Chile
  • Sandoz Investigational Site 2
    Tbilisi, Georgia
  • Sandoz Investigational Site
    Athens, Greece
  • Sandoz Investigational Site
    Thessaloniki, Greece
  • Sandoz Investigational Site
    Pisa, Italy
  • Sandoz Investigational Site
    Vilnius, Lithuania
  • Sandoz Investigational Site
    Kuala Lumpur, Malaysia
  • Sandoz Investigational Site
    Pulau Pinang, Malaysia
  • Sandoz Investigational Site
    Putrajaya, Malaysia
  • Sandoz Investigational Site
    Bacolod, Philippines
  • Sandoz Investigational Site
    Warsaw, Poland
  • Sandoz Investigational Site
    Lisbon, Portugal
  • Sandoz Investigational Site 1
    Busan, South Korea
  • Sandoz Investigational Site
    Daejeon, South Korea
  • Sandoz Investigational Site 2
    Seoul, South Korea
  • Sandoz Investigational Site 2
    Madrid, Spain
  • Sandoz Investigational Site
    Málaga, Spain
  • Sandoz Investigational Site
    Oviedo, Spain
  • Sandoz Investigational Site
    Santander, Spain
  • Sandoz Investigational Site
    Santiago de Compostela, Spain
  • Sandoz Investigational Site 2
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Jan 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 19, 2024
StartActual
Dec 19, 2024
Primary completionActual
Jan 23, 2026
CompletionActual
Jan 23, 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06587451
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Dec 19, 2024
Primary completion
Jan 23, 2026
Completion
Jan 23, 2026
Last update
Feb 24, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion